EN DE
Watch Shanghai Shenqi Pharmaceutical Investment Management Co Ltd B for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Shanghai Shenqi Pharmaceutical Investment Management Co Ltd B (900904) fair value: what the stock is really worth

As of Nov 16, 2026: fair value (intrinsic value) of Shanghai Shenqi Pharmaceutical Investment Management Co Ltd B stock $0.41, price $0.39, upside +5.1%, quality 58 out of 100. Rating: fairly valued. Calculated from audited financials with 24 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare CN · ISIN CNE0000003X8

SS Shanghai Shenqi Pharmaceutical Investment Management Co Ltd B logo Thin data Nov 14, 2026

Shanghai Shenqi Pharmaceutical Investment Management Co Ltd B

900904 · SHG

Solid company, but the stock is already about fairly priced and falling price: meets 1 of 3 rules.

Get notified free when this changes
Low debt 
Generates free cash flow 
Fair value $0.4100 · Fairly valued 
Quality 58/100 
Mixed Growth (revenue YoY −4.7 %/yr in CNY) 
Thin margins · 1.5% net margin (TTM) 
17.9% dividend yield · Payout strained
Mixed vs. peers (7/14) 
Revenue last quarter 12% below a year ago. 
Falling price (downtrend) 
Narrow moat 26/100 · thin data
Thin data 
Watch Shanghai Shenqi Pharmaceutical Investment Management Co Ltd B for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$0.9737 $0.3900 Fair Value $0.4100 Jun 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 14, 2026.

How to read this chart

60‑month range $0.3900 – $0.9737 · fair‑value band $0.3600 – $0.4800 · the $0.3900 price screens below the $0.4100 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. As of Nov 14, 2026.

Follow Shanghai Shenqi Pharmaceutical Investment Management Co Ltd B in your weekly email

Every Wednesday you see whether Shanghai Shenqi Pharmaceutical Investment Management Co Ltd B is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd., together with its subsidiaries, operates as a pharmaceutical manufacturing holding investment company in China.

Show moreShow less

The company engages in the research and development, and production of anti-tumor, cardiovascular, cerebrovascular, rheumatism bone pain, tonic and sedative, cold and cough, anti-fungal, gynecology, and other treatment fields.

Its products include prescription drugs and OTC products, including products include sodium cantharidate vitamin B6 injection, sodium cantharidin injection, loquat cough granules, strong loquat dew, loquat cough capsules, jinwu gutong capsules, coral ringworm net, jingwu capsules, quantianma capsules, yindan xintai pills, etc.

The company was founded in 1990 and is based in Shanghai, China.

Stock analysis

Shanghai Shenqi Pharmaceutical Investment Management Co Ltd B (900904) currently trades at $0.3900, while our model-based Fair Value estimate is $0.4100, so the stock looks roughly fairly valued today (gap 4.9%).

Show more

Valuation

Bull case: the Multiples group reads highest at a median of $0.6100 per share, and 11 of the 24 models we run sit above the $0.3900 price.

Bear case: the Growth Earnings group reads lowest at $0.1800, and 13 of the 24 models stay below the price. Data coverage for this calculation is low.

Scenario range: $0.3600 (bear) to $0.4800 (bull), the price of $0.3900 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 58/100 (solid quality), in the Healthcare sector.

Mixed Growth: Spin-off in 2024: revenue and profit before it include the divested business. Growth is measured afresh from 2024.

Shanghai Shenqi Pharmaceutical Investment Management Co Ltd B reported revenue of 2.0B CNY in FY2025 versus 2.3B CNY in FY2021, a compound −4.0%/yr. Reported net income was 38.2M CNY in FY2025, compounding −13.9%/yr from FY2021.

Key figures

Market cap $208M Micro · P/E ratio 40.3 · P/S ratio 0.12 · EPS (TTM) $0.0100 · Net margin 1.5% · Return on equity 1.3% · Return on assets (EBIT) 3.4% (5-year average) · Operating margin 5.0%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 26 out of 100 (low confidence).

What moves the price

The share trades about 27% below its 52-week high and at its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −11% fair-value upside, at 5%, 900904 screens cheaper than that median.

Fair Value models

Bear $0.3600 Fair Value $0.4100 Bull $0.4800
Price $0.3900 · Upside +5.1%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF $0.3500 $0.4000 $0.4900 82
Growth DCF $0.3500 $0.4100 $0.4800 80
Owner Earnings $0.2500 $0.2800 $0.3300 78
All 24 models by family
DCF Models
FCF DCF $0.3500 $0.4000 $0.4900 82
Owner Earnings $0.2500 $0.2800 $0.3300 78
5Y Revenue Exit $0.3800 $0.4900 $0.6400 74
5Y EBITDA Exit $0.5100 $0.7100 $0.9700 76
5Y P/E Exit $0.3200 $0.3900 $0.4600 72
10Y Revenue Exit $0.3600 $0.4300 $0.5000 68
10Y EBITDA Exit $0.4300 $0.5500 $0.6700 70
10Y P/E Exit $0.3300 $0.3700 $0.4100 65
Earnings-Based
Graham-Dodd $0.0700 $0.0900 $0.1000 67
EPV $0.3100 $0.3300 $0.3400 74
Dividend Discount
Gordon GGM $0.1800 $0.1900 $0.2100 69
DDM Multi-Stage $0.1800 $0.2100 $0.2400 67
Multiples
P/E Multiple $0.1800 $0.2400 $0.3000 63
P/S Multiple $0.1400 $0.1800 $0.2300 58
P/B Multiple $0.5200 $0.7000 $0.8700 55
EV/EBIT $0.5400 $0.6700 $0.8000 66
EV/EBITDA $0.7300 $0.9200 $1.12 67
EV/Revenue $0.4300 $0.5500 $0.6700 54
Asset-Based
NCAV (Graham) $0.1500 $0.2300 $0.2900 54
Growth DCF
Growth DCF $0.3500 $0.4100 $0.4800 80
Rev-Margin DCF $0.3800 $0.4900 $0.6300 74
Economic Profit
Residual Income $0.3800 $0.3900 $0.4200 76
ROIC Compounder $0.3100 $0.3300 $0.3400 72
Growth Earnings
Growth-Adj P/E $0.1300 $0.1800 $0.2300 68

Open the full fair value analysis →

Quality Score breakdown

Overall quality 58/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 31
How much profit the company makes from its sales and capital
Quality Growth 28
Are margins and returns getting better?
Cashflow 57
Do the profits arrive as real cash?
Financial strength 69
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 88
How calm the share price moves, does not count
Price momentum 23
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 4
Distance to the 52-week high, does not count
New shares 82
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 55/100
Spin-off in 2024: revenue and profit before it include the divested business. Growth is measured afresh from 2024.
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−13.0%
Earnings growth per share plus dividend.
Earnings per share, growth per year−13.0%
Dividend (yield on the price)0.0%
Profit margin 2021 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.4% → 6%

Growth Forecast

Price in line with expectations
The price assumes about as much growth as the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+2.5%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (figures in CNY, China: IMF forecast 1.7% a year to 2030, 1.4% from 2016 to 2025) that is about +0.8% a year for the price.

Watch 900904, get fair value alerts →

Compare Shanghai Shenqi Pharmaceutical Investment Management Co Ltd B with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - General · 74 stocks

Beats the industry median on 7/14 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 58 · Below median
Fair Value upside +5.1% · Above median
Profitability
Return on equity (12 months) 1.3% · Bottom 25%
Return on assets 1.2% · Bottom 25%
Net margin (12 months) 1.5% · Bottom 25%
Operating margin (12 months) 5.0% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −11.6% · Bottom 25%
Dividend yield (12 months) 17.9% · Top 25%
Balance sheet
Debt / equity 0.04× · Below median

Valuation Multiplesvs Drug Manufacturers - General median · lower = cheaper

P/E (12 months) 40.3× · Pricier than median
P/B 0.60× · Cheapest 25%
P/S (12 months) 0.75× · Cheapest 25%
Price / free cash flow (fiscal year) 15.2× · Cheapest 25%
EV/EBITDA 6.0× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)40 · sector 20
FUTURE (revenue growth)0 · sector 34
PAST (return on equity)5 · sector 41
HEALTH (low debt)98 · sector 93
DIVIDEND (yield)100 · sector 37

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - General stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Bristol-Myers Squibb Company BMY $62.93 $75.91 +21% vs 900904
Amgen Inc AMGN $462.32 $512.24 +11% vs 900904
Gilead Sciences, Inc GILD $167.58 $184.89 +10% vs 900904
Novartis AG NOVN CHF 135.76 CHF 123.08 −9% vs 900904
Merck & Co MRK $144.46 $129.26 −11% vs 900904
AbbVie Inc ABBV $294.55 $259.62 −12% vs 900904
Pfizer Inc PFE $28.86 $24.87 −14% vs 900904
Roche Holding RO CHF 414.20 CHF 326.56 −21% vs 900904
Johnson & Johnson, JNJ $282.55 $169.03 −40% vs 900904
Eli Lilly and Company LLY $1,432 $749.92 −48% vs 900904

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Shanghai Shenqi Pharmaceutical Investment Management Co Ltd B: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Shanghai Shenqi Pharmaceutical Investment Management Co Ltd B Fair Value". https://www.fairvalue-calculator.com/stock/900904

Frequently asked questions

Is Shanghai Shenqi Pharmaceutical Investment Management Co Ltd B (900904) overvalued or undervalued?
As of Nov 14, 2026, our model estimates a fair value of $0.4100 versus a price of $0.3900, about +5% upside (fairly valued).
What is the fair value of 900904?
Our model-based fair value for Shanghai Shenqi Pharmaceutical Investment Management Co Ltd B is $0.4100 (as of Nov 14, 2026), built from audited fundamentals. The current price: $0.3900.
What is the quality score of 900904?
Shanghai Shenqi Pharmaceutical Investment Management Co Ltd B has a Quality Score of 58/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Shanghai Shenqi Pharmaceutical Investment Management Co Ltd B (900904)?
Our model-based price target is the fair value of $0.4100 (as of Nov 14, 2026) from 24 valuation models. Cautious scenario $0.3600, optimistic scenario $0.4800. It is a calculation from audited fundamentals, not an analyst target.
What is the Shanghai Shenqi Pharmaceutical Investment Management Co Ltd B stock forecast for 2026?
Our models put fair value at $0.4100, about +5% upside versus a price of $0.3900 (fairly valued). Cautious scenario $0.3600, optimistic scenario $0.4800. The calculation is refreshed regularly with new filings.
What is the revenue of Shanghai Shenqi Pharmaceutical Investment Management Co Ltd B (900904)?
Shanghai Shenqi Pharmaceutical Investment Management Co Ltd B reported trailing-twelve-month revenue of about 1.8B CNY (latest available figure, as of Nov 14, 2026).
What growth is priced into Shanghai Shenqi Pharmaceutical Investment Management Co Ltd B (900904)?
For today's price to be fair in a discounted-cash-flow model, Shanghai Shenqi Pharmaceutical Investment Management Co Ltd B would have to grow free cash flow by 2.5 % per year for five years (discount rate 12.1 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew 1.4 % per year. As of Nov 14, 2026.
What discount rate (WACC) does the fair value of 900904 use?
Our models discount Shanghai Shenqi Pharmaceutical Investment Management Co Ltd B at 12.1 %: a base by market capitalisation (micro), damped by beta 0.61, country premium for China. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Shanghai Shenqi Pharmaceutical Investment Management Co Ltd B that is +2.5 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (12.1 %) and the same formula as our fair value.
How much growth has Shanghai Shenqi Pharmaceutical Investment Management Co Ltd B (900904) delivered so far?
Over the past 5 years revenue at Shanghai Shenqi Pharmaceutical Investment Management Co Ltd B grew 1.4 % a year. The price currently implies free-cash-flow growth of +2.5 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Shanghai Shenqi Pharmaceutical Investment Management Co Ltd B (900904) growing?
The median revenue growth in the sector is +7.3 % a year. That is the yardstick for the growth priced into Shanghai Shenqi Pharmaceutical Investment Management Co Ltd B (+2.5 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Shanghai Shenqi Pharmaceutical Investment Management Co Ltd B (900904)?
The free-cash-flow yield on the price is 6.57 %: that much free cash flow Shanghai Shenqi Pharmaceutical Investment Management Co Ltd B produces per unit of market value. When it exceeds the discount rate of our models (12.1 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Shanghai Shenqi Pharmaceutical Investment Management Co Ltd B (900904)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Shanghai Shenqi Pharmaceutical Investment Management Co Ltd B it is $0.4100 per share (as of Nov 14, 2026), against a price of $0.3900. It is the blended result of 24 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Shanghai Shenqi Pharmaceutical Investment Management Co Ltd B stock overvalued or undervalued in 2026?
As of Nov 14, 2026, 900904 trades below its calculated fair value: price $0.3900, fair value $0.4100, a gap of about +5% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 900904?
No. The price is what the market pays today ($0.3900); the fair value is what the company's own numbers justify ($0.4100). For Shanghai Shenqi Pharmaceutical Investment Management Co Ltd B the two are $0.0200 per share apart. That gap is exactly why we show both numbers side by side.
How much is Shanghai Shenqi Pharmaceutical Investment Management Co Ltd B worth?
The market values Shanghai Shenqi Pharmaceutical Investment Management Co Ltd B at about $208M (market capitalisation, as of Nov 14, 2026). Per share that is $0.3900; our models calculate a fair value of $0.4100 per share.
What do the bullish and bearish scenarios say about 900904?
Our models span a range for Shanghai Shenqi Pharmaceutical Investment Management Co Ltd B: cautious scenario $0.3600, base $0.4100, optimistic $0.4800 per share (as of Nov 14, 2026, price $0.3900). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 900904?
Shanghai Shenqi Pharmaceutical Investment Management Co Ltd B trades at a price-to-earnings ratio of 40.3 (as of Nov 14, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $0.4100 is built from several models across several years. Other multiples: P/B 0.6, P/S 0.8, EV/EBITDA 6.0.
How solid is the balance sheet of Shanghai Shenqi Pharmaceutical Investment Management Co Ltd B (900904)?
Balance-sheet figures for Shanghai Shenqi Pharmaceutical Investment Management Co Ltd B (as of Nov 14, 2026): return on equity 1.3%, debt of 0.04 per unit of equity. They feed the Quality Score of 58/100, which measures business quality independently of the share price.
How far is 900904 from its 52-week high?
Shanghai Shenqi Pharmaceutical Investment Management Co Ltd B trades at $0.3900, about 27% below its 52-week high of $0.5370 and at the low of $0.3900 (as of Nov 16, 2026). Distance from the high says nothing about value: that is what the fair value of $0.4100 is for.
Which stocks are comparable to Shanghai Shenqi Pharmaceutical Investment Management Co Ltd B?
From the same area (Healthcare) we also value Eli Lilly and Company, Johnson & Johnson,, AbbVie Inc, Roche Holding, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Shanghai Shenqi Pharmaceutical Investment Management Co Ltd B stock attractive at the current price?
The data as of Nov 14, 2026: price $0.3900, calculated fair value $0.4100 (+5%), Quality Score 58/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 900904 calculated?
We run Shanghai Shenqi Pharmaceutical Investment Management Co Ltd B through 24 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of $0.4100 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.6% above its aggregate fair value. Shanghai Shenqi Pharmaceutical Investment Management Co Ltd B currently trades 5% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Shanghai Shenqi Pharmaceutical Investment Management Co Ltd B (900904)?
The closing price on Nov 16, 2026 was $0.3900. Our model-based fair value is $0.4100, about +5% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Shanghai Shenqi Pharmaceutical Investment Management Co Ltd B right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Shanghai Shenqi Pharmaceutical Investment Management Co Ltd B

How large is the market capitalisation of Shanghai Shenqi Pharmaceutical Investment Management Co Ltd B (900904)?
The market capitalisation of Shanghai Shenqi Pharmaceutical Investment Management Co Ltd B is $208M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Shanghai Shenqi Pharmaceutical Investment Management Co Ltd B (900904)?
The price-to-sales ratio of Shanghai Shenqi Pharmaceutical Investment Management Co Ltd B is 0.12 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Shanghai Shenqi Pharmaceutical Investment Management Co Ltd B (900904)?
Earnings per share at Shanghai Shenqi Pharmaceutical Investment Management Co Ltd B are $0.0100 (price ÷ EPS = P/E 40.3). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Shanghai Shenqi Pharmaceutical Investment Management Co Ltd B (900904)?
The net margin of Shanghai Shenqi Pharmaceutical Investment Management Co Ltd B is 1.5% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Shanghai Shenqi Pharmaceutical Investment Management Co Ltd B (900904)?
The return on equity (ROE) of Shanghai Shenqi Pharmaceutical Investment Management Co Ltd B is 1.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Shanghai Shenqi Pharmaceutical Investment Management Co Ltd B (900904)?
On an EBIT basis the return on assets of Shanghai Shenqi Pharmaceutical Investment Management Co Ltd B is 3.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Shanghai Shenqi Pharmaceutical Investment Management Co Ltd B (900904)?
The operating margin of Shanghai Shenqi Pharmaceutical Investment Management Co Ltd B is 5.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Shanghai Shenqi Pharmaceutical Investment Management Co Ltd B (900904)?
Revenue at Shanghai Shenqi Pharmaceutical Investment Management Co Ltd B is down 11.6% versus a year earlier (3y avg −6.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Shanghai Shenqi Pharmaceutical Investment Management Co Ltd B (900904)?
Earnings per share at Shanghai Shenqi Pharmaceutical Investment Management Co Ltd B are down 33.3% versus a year earlier. How much earnings per share grew versus a year earlier.
Free · no account needed

Watch Shanghai Shenqi Pharmaceutical Investment Management Co Ltd B in the live analysis

One click puts Shanghai Shenqi Pharmaceutical Investment Management Co Ltd B on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.